Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Portable Bioprinter in Ischemic Wound Therapy: a Pilot Study.

Revokatova DP., Khristidis YI., Fayzullin AL., Ershov BP., Larionov DI., Nesterenko IV.

Animal Study on Chronic Wound, published in Sovrem Tekhnologii Med (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Sovrem Tekhnologii Med (2026)
Country
Russia (Federation)
Reported sample size
—
Source database
PubMed
PMID
41867640
DOI
10.17691/stm2026.18.1.02

Abstract (original English)

The aim of the study was to develop a novel approach to treatment of non-healing wounds by using a portable Biogan bioprinter and an ink based on fibrin-gelatin hydrogel and spheroids derived from mesenchymal stromal cells (MSCs) from adipose tissue in a model of ischemic pig wound. To simulate the wound, titanium sealing rings were used, which mechanically compressed the skin to create a local ischemic wound. A day after, the rings were removed, and the epidermis of the skin was excised. The wound was treated one day and 2 weeks after the wound infliction. For this purpose, a combined ink was applied to the wound surface using a portable Biogan bioprinter (the prototype was developed by the authors). An adapted passive mixer allowed uniform mixing of the bioink based on a fibrin-gelatin hydrogel and spheroids derived from human adipose MSCs. Wound closure rates were assessed over 36 days, followed by histological analysis. The use of inks based on fibrin-gelatin hydrogel and spheroids from adipose MSCs significantly accelerated healing, as evidenced by the reduction in the wound area compared to the control group and hydrogel-only group, as well as the complete restoration of all skin layers by day 36. The therapeutic effect of the developed approach was due to the spheroids in the bioinks and not to the hydrogel. The use of the developed mixer did not reduce the cell viabilit

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsWound HealingPilot ProjectsHumansMesenchymal Stem CellsSwineBioprintingIschemiaAdipose TissueFibrin

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research